AllPeptides.eu - Advanced Peptide Research
    Research-use-only hub
    1 variants

    Educational protocol hub

    Setmelanotide (Imcivree®): protocol variants and reconstitution resources

    Educational hub for Setmelanotide (Imcivree®), grouping 1 available protocol variant with links to the exact dosage and reconstitution pages.

    What this hub covers

    This page groups the available Setmelanotide (Imcivree®) protocol variants so readers can choose the exact vial-size guide without mixing formats.

    Reconstitution workflow

    Use the linked protocol pages and calculator resources to review concentration, diluent logic and unit conversions for the selected variant.

    Research-only context

    All information is educational and literature-focused. AllPeptides.eu does not sell peptides and does not provide medical advice.

    Available protocol variants

    Choose the exact guide you want to view.

    Setmelanotide (Imcivree®)

    10mg

    Setmelanotide (Imcivree®) is an FDA-approved MC4R agonist from Rhythm Pharmaceuticals for rare genetic forms of obesity (POMC, PCSK1, LEPR deficiency, Bardet-Biedl). 10 mg vial — reconstitute in 2 mL for 5 mg/mL.

    View protocol

    Related research resources

    Internal links that help readers and search engines understand this peptide topic cluster.

    References

    1. FDA Approval — Imcivree (2020) — Setmelanotide for POMC, PCSK1, LEPR deficiency obesity.
      View Source
    2. Lancet Diabetes Endocrinol (2020) — Clément K, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency.
      View Source
    3. Haqq AM et al. Lancet Diabetes Endocrinol 2022 — Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
      View Source
    4. EMA EPAR — Imcivree — European Medicines Agency public assessment report.
      View Source
    5. Collet TH et al. Mol Metab 2017 — Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
      View Source

    Educational and laboratory research information only. AllPeptides.eu does not sell peptides and does not provide medical advice or human-use instructions.

    Educational Navigator

    Educational reading navigator

    Find where to start in research peptide science through evidence, safety context and regulatory awareness.

    Covers

    Evidence levelsSafety contextRegulatory overviewLiterature readingResearch methodEducational reports
    5 min readEvidence-firstOpen access
    Open evidence framework

    New knowledge, new tools and selected updates from AllPeptides.eu